The Changes Of CXCR+/SDF-1 Expression From Bone Marrow And Its Significance In MDS Cases

Objective: To investigate the probably role of stromal cell derived factor-1 (SDF-1) and its receptor CXCR4 in the occurrence and progression of myeloid dysplasia syndrome (MDS) .Method: ELISA was used to determine the SDF-1 level in bone marrow supernatant and flow cytometry was used to measure the CXCR4 expressing CD34+cells in patients with AA, MDS, AML and healthy controls.Result: The level of SDF-1 in bone marrow supernatant from patients with AML, AA, MDS and controls were 7817, 6360, 9267 and 8268pg/ml, respectively. Statistically significant difference in level of SDF-1 was found between patients with AA and patients with MDS and low risk MDS (P=0.008,0.007), and no statistical significant difference was seen between patients with AML, AA, MDS and controls (P>0.05). The percentages of CXCR4 expressing CD34 + cell in patients with AML, AA, MDS and controls were 11%, 70%, 32% and 20%, respectively. MDS patients were divided into low risk and high risk groups according to IPSS score, the percentages of CXCR4 expressing CD34+ cell in low risk and high risk MDS patients were 37% and 15%, respectively (P=0.025).Conclusion: Bone marrow micro-environment might play a negative feedback role to inhibit the progression of MDS by regulating the level of CXCR4 expressing CD34+ cells, however, the changes of levels of SDF-1 were not significant.